<DOC>
	<DOCNO>NCT00236938</DOCNO>
	<brief_summary>This open-label , prospective study compare intravenous ( IV ) iron supplementation standard care anemic patent undergo peritoneal dialysis .</brief_summary>
	<brief_title>Efficacy Safety Venofer ( Iron Sucrose Injection USP ) Patients Receiving Peritoneal Dialysis</brief_title>
	<detailed_description>This open-label , prospective study compare IV iron supplementation standard care anemic patient undergo peritoneal dialysis . After successfully complete 6 month enrollment period , qualify patient randomize receive 1000mg IV iron four week period , iron supplementation . Erythropoietin regimen remain stable . Patients follow day 71 safety efficacy .</detailed_description>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Hemoglobin &gt; = 9.5 &lt; = 11.5 g/dL . Ferritin &lt; = 500 ng/ml . Serum Transferrin Saturation ( TSAT ) &lt; = 25 % . Stable erythropoietin ( EPO ) Regimen 8 week . No iron last 4 week randomization . Known Sensitivity Iron Sucrose . Suffering concomitant severe diseases liver &amp; cardiovascular system . Pregnancy / Lactation . Inadequate dialysis . Current treatment asthma . Significant blood loss . Probability need transfusion transfusion within 1 week enrollment . Anticipated major surgery . Hemochromatosis / hemosiderosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>iron</keyword>
	<keyword>peritoneal dialysis</keyword>
	<keyword>anemia</keyword>
</DOC>